Curacyte Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Out of Business

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Liquidation

Curacyte General Information

Description

Developer of advanced biopharmaceutics intended to treat acute and critical diseases. The company's advanced biopharmaceutics develops new medicines in the areas of hematology, antithrombosis, and oncology, enabling people to avail the new generation of drugs.

Contact Information

Website
www.curacyte.eu
Formerly Known As
VitaResc Biotech
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • C/o Dornbach GmbH
  • Arnulfstraße 39
  • 80636 Munich
  • Germany
+49 089
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • C/o Dornbach GmbH
  • Arnulfstraße 39
  • 80636 Munich
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Curacyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 30-Aug-2016 Completed Bankruptcy: Liquidation
5. Later Stage VC 29-Dec-2012 Completed Generating Revenue
4. Grant Completed Generating Revenue
3. Secondary Transaction - Private 30-Jun-2012 Completed Generating Revenue
2. Later Stage VC (Series C) 20-Dec-2005 $37.3M $76.2M Completed Generating Revenue
1. Early Stage VC 01-Jan-2000 $38.9M $38.9M Completed Generating Revenue
To view Curacyte’s complete valuation and funding history, request access »

Curacyte Patents

Curacyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2008107176-A1 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors Inactive 06-Mar-2007
WO-2008077631-A1 Substituted 5h-pyrimidol[5,4-b]indoles, method for the production thereof, and use thereof for treating non-solid malignant tumors of the blood-producing system Inactive 22-Dec-2006
WO-2008049595-A1 Trypsin-like serine protease inhibitors, and their preparation and use Inactive 24-Oct-2006
WO-2008049595-A9 Trypsin-like serine protease inhibitors, and their preparation and use Inactive 24-Oct-2006
DE-102005044319-A1 2- (aminomethyl) -5-chloro-benzylamide derivatives and their use as inhibitors of coagulation factor xa Inactive 16-Sep-2005 C07K5/06139
To view Curacyte’s complete patent history, request access »

Curacyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Curacyte FAQs

  • When was Curacyte founded?

    Curacyte was founded in 1998.

  • Where is Curacyte headquartered?

    Curacyte is headquartered in Munich, Germany.

  • What is the size of Curacyte?

    Curacyte has 15 total employees.

  • What industry is Curacyte in?

    Curacyte’s primary industry is Therapeutic Devices.

  • Is Curacyte a private or public company?

    Curacyte is a Private company.

  • What is Curacyte’s current revenue?

    The current revenue for Curacyte is .

  • How much funding has Curacyte raised over time?

    Curacyte has raised $85.4M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process